Biomaterials-Based Vaccination Strategies for the Induction of CD8+T Cell Responses

Charles B. Chesson, Shaunte Ekpo-Otu, Janice Endsley, Jai S. Rudra

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Natural and synthetic biomaterials are increasingly being used for the development of vaccines and immunotherapies as alternatives to traditional live-attenuated formulations due to their improved safety profiles and no risk of reversion to virulence. Polymeric materials in particular enjoy attention due to the ease of fabrication, control over physicochemical properties, and their wide range of immunogenicity. While the majority of studies focus on inducing protective antibody responses, in recent years, materials-based strategies for the delivery of antigens and immunomodulators to improve CD8+T cell immunity against infectious and non-infectious diseases have gained momentum. Notably, platforms based on polymeric nanoparticles, liposomes, micelles, virus-like particles, self-assembling peptides and peptidomimetics, and multilayer thin films show considerable promise in preclinical studies. In this Review, we first introduce the concepts of CD8+T cell activation, effector and memory functions, and cytotoxic activity, followed by vaccine design for eliciting robust and protective long-lived CD8+T cell immunity. We then discuss different materials-based vaccines developed in the past decade to elicit CD8+T cell responses based on molecular composition or fabrication methods and conclude with a summary and glimpse at the future trends in this area.

Original languageEnglish (US)
Pages (from-to)126-143
Number of pages18
JournalACS Biomaterials Science and Engineering
Volume3
Issue number2
DOIs
StatePublished - Feb 13 2017

Fingerprint

T-cells
Biocompatible Materials
Biomaterials
Vaccines
Peptidomimetics
Fabrication
Liposomes
Multilayer films
Immunologic Factors
Micelles
Antigens
Viruses
Antibodies
Peptides
Particles (particulate matter)
Momentum
Chemical activation
Nanoparticles
Data storage equipment
Thin films

Keywords

  • biomaterial
  • CD8T cell
  • cellular immunity
  • polymer
  • vaccine

ASJC Scopus subject areas

  • Biomaterials
  • Biomedical Engineering

Cite this

Biomaterials-Based Vaccination Strategies for the Induction of CD8+T Cell Responses. / Chesson, Charles B.; Ekpo-Otu, Shaunte; Endsley, Janice; Rudra, Jai S.

In: ACS Biomaterials Science and Engineering, Vol. 3, No. 2, 13.02.2017, p. 126-143.

Research output: Contribution to journalArticle

Chesson, Charles B. ; Ekpo-Otu, Shaunte ; Endsley, Janice ; Rudra, Jai S. / Biomaterials-Based Vaccination Strategies for the Induction of CD8+T Cell Responses. In: ACS Biomaterials Science and Engineering. 2017 ; Vol. 3, No. 2. pp. 126-143.
@article{1d09129efb014b1fb2daf51a3cdc66fc,
title = "Biomaterials-Based Vaccination Strategies for the Induction of CD8+T Cell Responses",
abstract = "Natural and synthetic biomaterials are increasingly being used for the development of vaccines and immunotherapies as alternatives to traditional live-attenuated formulations due to their improved safety profiles and no risk of reversion to virulence. Polymeric materials in particular enjoy attention due to the ease of fabrication, control over physicochemical properties, and their wide range of immunogenicity. While the majority of studies focus on inducing protective antibody responses, in recent years, materials-based strategies for the delivery of antigens and immunomodulators to improve CD8+T cell immunity against infectious and non-infectious diseases have gained momentum. Notably, platforms based on polymeric nanoparticles, liposomes, micelles, virus-like particles, self-assembling peptides and peptidomimetics, and multilayer thin films show considerable promise in preclinical studies. In this Review, we first introduce the concepts of CD8+T cell activation, effector and memory functions, and cytotoxic activity, followed by vaccine design for eliciting robust and protective long-lived CD8+T cell immunity. We then discuss different materials-based vaccines developed in the past decade to elicit CD8+T cell responses based on molecular composition or fabrication methods and conclude with a summary and glimpse at the future trends in this area.",
keywords = "biomaterial, CD8T cell, cellular immunity, polymer, vaccine",
author = "Chesson, {Charles B.} and Shaunte Ekpo-Otu and Janice Endsley and Rudra, {Jai S.}",
year = "2017",
month = "2",
day = "13",
doi = "10.1021/acsbiomaterials.6b00412",
language = "English (US)",
volume = "3",
pages = "126--143",
journal = "ACS Biomaterials Science and Engineering",
issn = "2373-9878",
publisher = "American Chemical Society",
number = "2",

}

TY - JOUR

T1 - Biomaterials-Based Vaccination Strategies for the Induction of CD8+T Cell Responses

AU - Chesson, Charles B.

AU - Ekpo-Otu, Shaunte

AU - Endsley, Janice

AU - Rudra, Jai S.

PY - 2017/2/13

Y1 - 2017/2/13

N2 - Natural and synthetic biomaterials are increasingly being used for the development of vaccines and immunotherapies as alternatives to traditional live-attenuated formulations due to their improved safety profiles and no risk of reversion to virulence. Polymeric materials in particular enjoy attention due to the ease of fabrication, control over physicochemical properties, and their wide range of immunogenicity. While the majority of studies focus on inducing protective antibody responses, in recent years, materials-based strategies for the delivery of antigens and immunomodulators to improve CD8+T cell immunity against infectious and non-infectious diseases have gained momentum. Notably, platforms based on polymeric nanoparticles, liposomes, micelles, virus-like particles, self-assembling peptides and peptidomimetics, and multilayer thin films show considerable promise in preclinical studies. In this Review, we first introduce the concepts of CD8+T cell activation, effector and memory functions, and cytotoxic activity, followed by vaccine design for eliciting robust and protective long-lived CD8+T cell immunity. We then discuss different materials-based vaccines developed in the past decade to elicit CD8+T cell responses based on molecular composition or fabrication methods and conclude with a summary and glimpse at the future trends in this area.

AB - Natural and synthetic biomaterials are increasingly being used for the development of vaccines and immunotherapies as alternatives to traditional live-attenuated formulations due to their improved safety profiles and no risk of reversion to virulence. Polymeric materials in particular enjoy attention due to the ease of fabrication, control over physicochemical properties, and their wide range of immunogenicity. While the majority of studies focus on inducing protective antibody responses, in recent years, materials-based strategies for the delivery of antigens and immunomodulators to improve CD8+T cell immunity against infectious and non-infectious diseases have gained momentum. Notably, platforms based on polymeric nanoparticles, liposomes, micelles, virus-like particles, self-assembling peptides and peptidomimetics, and multilayer thin films show considerable promise in preclinical studies. In this Review, we first introduce the concepts of CD8+T cell activation, effector and memory functions, and cytotoxic activity, followed by vaccine design for eliciting robust and protective long-lived CD8+T cell immunity. We then discuss different materials-based vaccines developed in the past decade to elicit CD8+T cell responses based on molecular composition or fabrication methods and conclude with a summary and glimpse at the future trends in this area.

KW - biomaterial

KW - CD8T cell

KW - cellular immunity

KW - polymer

KW - vaccine

UR - http://www.scopus.com/inward/record.url?scp=85012288938&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012288938&partnerID=8YFLogxK

U2 - 10.1021/acsbiomaterials.6b00412

DO - 10.1021/acsbiomaterials.6b00412

M3 - Article

AN - SCOPUS:85012288938

VL - 3

SP - 126

EP - 143

JO - ACS Biomaterials Science and Engineering

JF - ACS Biomaterials Science and Engineering

SN - 2373-9878

IS - 2

ER -